ALPA · NSE
Alpa Laboratories Limited
₹59.07
-2.19% (-₹1.32)
Prev. close
₹60.39
Volume
87,569
Delivery %
44.9%
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Alpa Laboratories Limited
Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It offers ethical, generic, and over the counter medicines. The company provides tablets, capsules, injections, syrups, ointments, creams, eye drops, and other dosage forms for human and veterinary healthcare, as well as aquaculture products, including probiotics, deodorizer, minerals, feed supplements, and disinfectant. The company was founded in 1967 and is based in Indore, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mahendra Singh Chawla
Headquarters
Indore
Employees
457
Website
alpalabs.inExchange
View on NSE ↗Key stats
Market cap
₹124.29 Cr
P/E ratio (TTM)
29.0
EPS (TTM)
₹2.04
Beta (1Y · daily vs NIFTY 50)
1.11
Beta (5Y · monthly vs NIFTY 50)
1.89
Shares float
85.24 L
EPS · quarter ended Jun 2026
₹0.49
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹97.55 Cr | ₹112.27 Cr | ₹92.44 Cr | ₹108.74 Cr | ₹111.63 Cr | ₹105.81 Cr | |
| EBITDA | ₹12.09 Cr | ₹21.46 Cr | ₹17.30 Cr | ₹23.00 Cr | ₹27.90 Cr | ₹19.05 Cr |
| ₹7.24 Cr | ₹14.09 Cr | ₹12.63 Cr | ₹16.78 Cr | ₹19.50 Cr | ₹15.01 Cr | |
| Diluted EPS | ₹3.45 | ₹6.7 | ₹5.9 | ₹8.01 | — | ₹7.13 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹140.37 Cr | ₹155.24 Cr | ₹167.00 Cr | ₹182.00 Cr | ₹223.00 Cr | ₹242.00 Cr | |
| ₹19.20 L | ₹5.85 Cr | ₹2.30 Cr | ₹5.25 Cr | ₹3.43 L | ₹2.51 Cr | |
| Stockholders' equity | ₹108.00 Cr | ₹122.00 Cr | ₹135.00 Cr | ₹152.00 Cr | ₹171.00 Cr | ₹186.00 Cr |
Current assets, Non-current assets, CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-1.51 Cr | ₹1.98 Cr | ₹8.90 Cr | ₹3.65 Cr | ₹18.32 Cr | ₹9.95 Cr | |
| Investing cash flow | ₹5.88 Cr | ₹-15.59 Cr | ₹1.17 Cr | ₹-13.34 Cr | ₹-12.36 Cr | ₹-11.56 Cr |
| ₹-2.65 L | ₹5.60 Cr | ₹-3.48 Cr | ₹2.58 Cr | ₹-5.44 Cr | ₹2.22 Cr | |
| Capital expenditure | ₹-11.13 Cr | ₹-17.12 Cr | ₹-1.13 Cr | ₹-6.39 Cr | ₹-11.38 Cr | ₹-3.24 Cr |
| End cash position | ₹10.52 Cr | ₹2.51 Cr | ₹8.81 Cr | ₹3.11 Cr | ₹3.62 Cr | ₹4.24 Cr |
Dividends paid has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22–Dec 25(16Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|
| Promoter | 56.66% | 57.29% | 57.19% |
| Public | 43.34% | 42.71% | 42.81% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Alpa Laboratories Limited | ₹124.29 Cr | ₹59.07 | 29.0 | 0.67 | 8.1% | 0.01 | -6.0% | -36.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Show all 19
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.